CMS launches coverage determination for beta-amyloid PET scans following Alzheimer’s drug approval

The Centers for Medicare & Medicaid Services is assessing whether it should reimburse for Alzheimer’s disease therapy directed via beta-amyloid PET scans results.

On June 7, the Food and Drug Administration made the controversial move to approve Biogen’s monoclonal antibody treatment for Alzheimer’s known as Aduhelm. And now, following calls from imaging advocates, CMS is opening a national coverage determination (NCD) into amyloid PET’s role in guiding treatment decision making.

CMS specifically mentioned Aduhelm in its NCD, noting it’s interested in comments and evidence regarding five specific questions.

Source: https://www.healthimaging.com/topics/molecular/amyloid-pet-cms-coverage-alzheimers-drug